Evoke Pharma (NASDAQ:EVOK) released its earnings results on Thursday. The specialty pharmaceutical company reported ($0.07) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.02, Fidelity Earnings reports.
Shares of EVOK opened at $0.90 on Friday. The firm has a market cap of $20.70 million, a PE ratio of -1.96 and a beta of 1.53. The company’s fifty day moving average is $0.86 and its two-hundred day moving average is $0.81. Evoke Pharma has a fifty-two week low of $0.50 and a fifty-two week high of $3.26.
Several research firms have commented on EVOK. ValuEngine raised shares of Evoke Pharma from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. HC Wainwright reaffirmed a “hold” rating on shares of Evoke Pharma in a research note on Friday, August 9th. Finally, Zacks Investment Research cut shares of Evoke Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, October 23rd.
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Featured Story: The Discount Rate – What You Need to Know
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.